Product Images Clopidogrel Bisulfate

Description: This is a drug information label for Clopidogrel Tab, a generic medication for Plavix. The tablet contains 97.875 mg of clopidogrel bisulfate USP equivalent to 75 mg of clopidogrel base. The package size and expiration date are not provided. It is manufactured by ScieGen Pharmaceuticals. The label warns against transferring the drug to anyone other than the patient for whom it was prescribed. The label also contains instructions in Spanish. The product numbers and lot numbers are listed for several variations of the drug.*

Each tablet contains 97.875 mg of Clopidogrel bisulfate, USP. The standard adult dosage is not available. The tablets should be stored at room temperature (15° to 30°C (59° to 86°F)). The medication guide should be dispensed to each patient by the pharmacist. The tablets are manufactured by ScieGen Pharmaceuticals, Inc. and the National Drug Code (NDC) is 50228-124-90. This medication is prescription-only (Rx only).*

The text describes a figure (Figure 1) showing the exposure to Clopidogrel Active Metabolite after taking multiple doses of Clopidogrel 75 mg alone or with Proton Pump Inhibitors (PPIs). The figure indicates the effect of co-administered PPIs on the active metabolite AUC with mean and 90% confidence interval for Deslansoprazole (60 mg), Lansoprazole (0 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). The figure also shows a change relative to Clopidogrel administered alone.*

This is a figure representing the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke between placebo (+ aspirin) and clopidogrel (+ aspirin*) groups over a period of 12 months. The p-value was 0.00009. Other standard therapies were used as appropriate.*

The text describes the results of the COMMIT study for the cumulative event rates of death before the first discharge with Placebo and Clopidogrel treatments. Placebo had 1845 deaths (8.1%), while Clopidogrel had 1726 deaths (7.5%). There was a 7% proportional risk reduction (p=0.03) with Clopidogrel. The graph shows the cumulative event rates over time up to 28 days since randomization. All treated patients also received aspirin. Therefore, the text provides information on the efficacy of Clopidogrel compared to Placebo in reducing death rates in patients.*

The text describes the results of a study comparing the effects of placebo and clopidogrel on patients with a certain condition. The study found that 10.1% of the patients on placebo experienced an event, while 9.2% of the patients on clopidogrel did. There was a 9% proportional risk reduction (p = 0.002) in death, re-infarction, or stroke before the first discharge in the clopidogrel group. The study followed the patients for up to 28 days, plotting the number of events over time.*

This is a table that shows the cumulative event rate for fatal or non-fatal vascular events for aspirin and clopidogrel over 6, 12, 18, and 24 months of follow-up. The table has a total of 3 rows and includes symbols @ and &.*